<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1965">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814914</url>
  </required_header>
  <id_info>
    <org_study_id>K034-120</org_study_id>
    <nct_id>NCT04814914</nct_id>
  </id_info>
  <brief_title>An Observational Clinical Study to Evaluate COVID-19 Symptoms in &quot;Long Hauler&quot; Patients Who Participated in K031-120 or K032-120</brief_title>
  <official_title>An Observational Study to Evaluate the Presence of Symptoms After COVID-19 Infection in Patients Who Participated in K031-120 or K032-120 Study (&quot;Long Hauler&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaleido Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaleido Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational clinical study aims to evaluate the presence of symptoms of COVID-19&#xD;
      infection in patients who participated in K031-120 or K032-120 (&quot;long hauler&quot;).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with persistent COVID-19 symptoms for at least 12-weeks post-randomization in K031-120 or K032-120 study.</measure>
    <time_frame>12-weeks from randomization in K031-120 or K032-120</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>KB109 + Self Supportive Care (SSC)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Self Supportive Care (SSC) Alone</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>KB109 + Self Supportive Care</intervention_name>
    <description>KB109 is a novel glycan</description>
    <arm_group_label>KB109 + Self Supportive Care (SSC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Self Supportive Care (SSC) Alone</intervention_name>
    <description>Self Supportive Care (SSC) Alone</description>
    <arm_group_label>Self Supportive Care (SSC) Alone</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who participated in K031-120 or K032-120 study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have consented to participate over the telephone&#xD;
&#xD;
          -  Have been randomized in either the K031-120 or K032-120 study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have withdrawn consent from K031-120 or K032-120&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Mark Wingertzahn, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kaleido Biosciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Wingertzahn, PhD</last_name>
    <phone>(617) 674-9000</phone>
    <email>clinicalstudies@kaleido.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HealthStar Research, LLC</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quad Clinical Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60643</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Corona Virus</keyword>
  <keyword>Corona Virus Disease</keyword>
  <keyword>Kaleido</keyword>
  <keyword>Kaleido Biosciences</keyword>
  <keyword>KB109</keyword>
  <keyword>Oligosaccharide</keyword>
  <keyword>Glycan</keyword>
  <keyword>Microbiome metabolic therapy</keyword>
  <keyword>MMT</keyword>
  <keyword>Supportive Self Care</keyword>
  <keyword>SSC</keyword>
  <keyword>Telemedicine</keyword>
  <keyword>K031-120</keyword>
  <keyword>K032-120</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

